Aims/hypothesis: Type 1 diabetes is considered non-reversible at end-stage disease when there is no measurable insulin production. However, there are indications that insulin-producing beta cells could be present or return if autoimmunity could be controlled. We therefore sought to determine whether immunosuppression therapy can reinstate beta cell function in patients with long-term type 1 diabetes. Methods: We examined pancreatic beta cell function in 22 patients with long-term type 1 diabetes (median disease duration 27 years), who had been receiving rapamycin monotherapy (0.1 mg/kg; target trough levels 8-10 ng/ml; 26-314 days) as pre-conditioning for islet transplantation. As control, beta cell function was measured in 14 patients (median disease duration 17 years) who were waiting for an islet transplant without rapamycin pre-conditioning. Results: Fasting C-peptide increased from <0.03 nmol/l (0.0066 nmol/l, interquartile range [IQR] 0.0003-0.023) at baseline to 0.039 nmol/l (IQR 0.0066-0.096) at end of rapamycin monotherapy (p < 0.005). In 12 patients, fasting C-peptide increased to >0.076 nmol/l (C-peptide responders). Exogenous insulin requirement decreased from 0.64 U/kg daily (IQR 0.56-0.72) to 0.57 U/kg (IQR 0.45-0.70; p = 0.01), but this reduction was significant only in the 12C-peptide-responsive patients. Rapamycin monotherapy was also associated with a decrease in insulin antibody titre (median decrease 110 to 35.9 U/ml; p < 0.001) and fasting serum proinsulin (median decrease 0.51 to 0.28 pmol/l; p = 0.001). All variables remained unchanged in the 14 control patients. Conclusions/interpretation: Therapies to reinstate beta cell function may be applicable to patients with long-term C-peptide-negative type 1 diabetes. Trial registration: ClinicalTrial.gov NCT01060605 Funding: This study was funded by Telethon Italy and the Juvenile Diabetes Research Foundation (JT01Y01 and grant no. 6-2006-1098) and the European Union (DIAPREPP Project, FP7-HEALTH-202013). E. Bonifacio is funded by the Deutsche Forschungsgemeinschaft (FZ111). © 2010 Springer-Verlag
Piemonti, L., Maffi, P., Monti, L., Lampasona, V., Perseghin, G., Magistretti, P., et al. (2011). Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. DIABETOLOGIA, 54(2), 433-439.
Citazione: | Piemonti, L., Maffi, P., Monti, L., Lampasona, V., Perseghin, G., Magistretti, P., et al. (2011). Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. DIABETOLOGIA, 54(2), 433-439. |
Tipo: | Articolo in rivista - Articolo scientifico |
Carattere della pubblicazione: | Scientifica |
Presenza di un coautore afferente ad Istituzioni straniere: | Si |
Titolo: | Beta cell function during rapamycin monotherapy in long-term type 1 diabetes |
Autori: | Piemonti, L; Maffi, P; Monti, L; Lampasona, V; Perseghin, G; Magistretti, P; Secchi, A; Bonifacio, E |
Autori: | |
Data di pubblicazione: | 2011 |
Lingua: | English |
Rivista: | DIABETOLOGIA |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s00125-010-1959-6 |
Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
diabetologia 11-1.pdf | N/A | Administrator Richiedi una copia |